Teva Pharmaceutical Industries (NYSE: TEVA) is considered a top growth stock under $25. Bank of America raised its price target to $24, expecting steady growth due to consistent performance. TEVA offers generic, specialty, and OTC products. Other AI stocks may offer better investment opportunities.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing